文章摘要
骆玉霜,李会.SPP1基因在恶性肿瘤中的作用及研究进展[J].安徽医药,待发表.
SPP1基因在恶性肿瘤中的作用及研究进展
投稿时间:2024-04-18  录用日期:2024-05-27
DOI:
中文关键词: SPP1  肿瘤  免疫抑制  肿瘤标记物  耐药
英文关键词: 
基金项目:2023年度青海省“昆仑英才高端创新创业人才”项目——消化道肿瘤创新团队。
作者单位邮编
骆玉霜 青海大学附属医院 810001
李会* 青海大学附属医院 
摘要点击次数: 122
全文下载次数: 0
中文摘要:
      磷酸蛋白酶1(SPP1)是糖蛋白家族成员之一,广泛表达于肺腺癌、胃癌、食管鳞状细胞癌等肿瘤组织,在多种肿瘤中具有生物标志物的特性。SPP1通过与配体相互作用,影响下游信号通路,使肿瘤免疫微环境处于抑制状态,从而介导多种恶性肿瘤生长、浸润和转移;SPP1亦可通过磷酯酰肌醇3-激酶(PI3K)/蛋白激酶B(AKT)信号通路介导卵巢癌、肝细胞癌出现耐药,而研究表明SPP1抑制剂可以逆转肿瘤耐药,减慢肿瘤发展过程。综上,SPP1有希望成为恶性肿瘤潜在的诊断治疗靶点之一,本文就SPP1基因在恶性肿瘤研究进展作一综述。
英文摘要:
      Phosphoprotein 1 (SPP1), a member of the glycoprotein family, is extensively expressed in lung adenocarcinoma, gastric cancer, esophageal squamous cell carcinoma, and other tumor tissues, and possesses biomarker properties in a multitude of tumors. By interacting with ligands, SPP1 influences the downstream signaling pathway and impedes the tumor immune microenvironment, thereby facilitating the growth, invasion, and metastasis of various malignant tumors. SPP1 is also capable of mediating drug resistance in ovarian cancer and other forms of cancer. Additionally, SPP1 can also mediate drug resistance in ovarian cancer and hepatocellular carcinoma through the phosphoinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway. Studies have demonstrated that SPP1 inhibitors can reverse tumor drug resistance and slow down tumor progression. In summary, SPP1 possesses the potential to be among the viable targets for the diagnosis and treatment of malignant tumors. This article reviews the advancements in research regarding the SPP1 gene in malignant tumors.
  查看/发表评论  下载PDF阅读器
关闭

分享按钮